0000904454-18-000297.txt : 20180423 0000904454-18-000297.hdr.sgml : 20180423 20180423164419 ACCESSION NUMBER: 0000904454-18-000297 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20180411 FILED AS OF DATE: 20180423 DATE AS OF CHANGE: 20180423 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Hoffmann Rolf K CENTRAL INDEX KEY: 0001737142 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36066 FILM NUMBER: 18769303 MAIL ADDRESS: STREET 1: LORBEERWEG 7 CITY: WEGGIS STATE: V8 ZIP: CH-6353 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Paratek Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001178711 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330960223 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 75 PARK PLAZA STREET 2: 4TH FLOOR CITY: BOSTON STATE: MA ZIP: 02116 BUSINESS PHONE: (617) 807-6600 MAIL ADDRESS: STREET 1: 75 PARK PLAZA STREET 2: 4TH FLOOR CITY: BOSTON STATE: MA ZIP: 02116 FORMER COMPANY: FORMER CONFORMED NAME: Transcept Pharmaceuticals Inc DATE OF NAME CHANGE: 20090130 FORMER COMPANY: FORMER CONFORMED NAME: NOVACEA INC DATE OF NAME CHANGE: 20020724 3 1 edgar.xml PRIMARY DOCUMENT X0206 3 2018-04-11 0 0001178711 Paratek Pharmaceuticals, Inc. PRTK 0001737142 Hoffmann Rolf K C/O PARATEK PHARMACEUTICALS, INC. 75 PARK PLAZA, 4TH FLOOR BOSTON MA 02116 1 0 0 0 Common Stock 3500 D Stock Option (right to buy) 20.60 2027-05-31 Common Stock 12000 D Represents restricted stock units granted to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan, pursuant to a Consulting Agreement, dated June 1, 2017, between the Issuer and the Reporting Person. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. The restricted stock units shall vest on June 1, 2018, subject to the Reporting Person's continued service with the Issuer as of the vesting date. The stock option was granted to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan, pursuant to a Consulting Agreement, dated June 1, 2017, between the Issuer and the Reporting Person. The stock option shall vest as to 1/12 of the shares subject to the stock option on July 31, 2017, and on the last day of each successive month thereafter until fully vested, subject to the Reporting Person's continued service with the Issuer through each vesting date. The exercise price is equal to the closing sales price per share of Common Stock as reported on The Nasdaq Global Market on the date of grant. Exhibit List - Exhibit 24 - Power of Attorney /s/ William M. Haskel, Attorney-in-Fact for Rolf K. Hoffmann 2018-04-23 EX-24 2 attach_3.htm ROLF HOFFMANN POWER OF ATTORNEY
Exhibit 24

POWER OF ATTORNEY

Know all by these present, that the undersigned hereby constitutes and appoints each of Douglas W. Pagán, William M. Haskel, Thomas Danielski and Christopher Comeau, signing singly, as the undersigned's true and lawful attorney-in-fact to:

(1)
execute for and on behalf of the undersigned, Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended (the "Act"), and the rules thereunder;

(2)
do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4 or 5, complete and execute any amendment or amendments thereto, and timely file such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and

(3)
take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all the acts such attorney-in-fact shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted.  The undersigned acknowledges that each of the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, is not assuming any of the undersigned's responsibilities to comply with Section 16 of the Act.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by Paratek Pharmaceuticals, Inc., unless earlier revoked by the undersigned in a signed writing delivered to each of the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of April 9, 2018.

       
 
By:  
 /s/ Rolf K. Hoffmann      
 
   
Name:  Rolf K. Hoffmann